Liu Jie, Wu Hui, Xia Sheng-Li
Shanghai Jiao Tong University School of Medicine Library, No. 280, South Chongqing Road, Shanghai 200025, China.
Department of Orthopedics, Shanghai University of Medicine & Health Sciences Affiliated Zhoupu Hospital, 1500 Zhoupu Zhouyuan Road, Pudong New Area, Shanghai 201318, China.
Vaccines (Basel). 2023 Mar 15;11(3):665. doi: 10.3390/vaccines11030665.
Coronavirus disease 2019 (COVID-19) vaccine has effectively suppressed the spread of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and alleviated its symptoms, but there are also many adverse events. Joint diseases caused by COVID-19 vaccine have been reported in many studies. Some are well-controlled arthritis patients who developed arthritis after COVID-19 vaccination, while others are new-onset joint pain and swelling problems after COVID-19 vaccination. The purpose of this systematic review is to examine the literature reports in existing databases and analyze the incidence of new-onset arthritis after COVID-19 vaccination. We included 31 eligible articles and described 45 patients, ranging in age from 17 to over 90, with more females than males. The majority (84.4%) of patients received the adenovirus vector vaccine (ChAdOx1) and the mRNA-based vaccine (BNT126b2 and mRNA-1273). Most (64.4%) patients developed joint-related symptoms after the first dose of vaccine, and 66.7% developed symptoms within the first week of vaccination. The joint symptoms involved were mainly joint swelling, joint pain, limited range of motion, and so on. A total of 71.1% of the patients involved multiple joints, both large and small; 28.9% of patients involved only a single joint. Some (33.3%) patients were confirmed by imaging, and the most common diagnoses were bursitis and synovitis. Two nonspecific inflammatory markers, erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP), were monitored in almost all cases, and all patients showed varying degrees of increase in these two markers. Most of the patients received the treatment of glucocorticoid drugs or nonsteroidal anti-inflammatory drugs (NSAIDs). Clinical symptoms markedly improved in most patients, with 26.7% making a full recovery and no relapse after a few months of follow-up. To determine whether there is a causal relationship between COVID-19 vaccination and the triggering of arthritis, large-scale and well-controlled research studies are needed in the future to verify this relationship and to further study its pathogenesis in detail. Clinicians should raise awareness of this complication with a view to early diagnosis and appropriate treatment.
2019冠状病毒病(COVID-19)疫苗有效抑制了严重急性呼吸综合征冠状病毒2(SARS-CoV-2)的传播并缓解了其症状,但也存在许多不良事件。许多研究报告了COVID-19疫苗引起的关节疾病。一些是病情得到良好控制的关节炎患者在接种COVID-19疫苗后出现关节炎,而另一些是接种COVID-19疫苗后出现新的关节疼痛和肿胀问题。本系统评价的目的是查阅现有数据库中的文献报告,并分析接种COVID-19疫苗后新发关节炎的发生率。我们纳入了31篇符合条件的文章,描述了45例患者,年龄从17岁到90多岁,女性多于男性。大多数(84.4%)患者接种了腺病毒载体疫苗(ChAdOx1)和基于信使核糖核酸的疫苗(BNT162b2和mRNA-1273)。大多数(64.4%)患者在接种第一剂疫苗后出现关节相关症状,66.7%的患者在接种疫苗的第一周内出现症状。涉及的关节症状主要有关节肿胀、关节疼痛、活动范围受限等。共有71.1%的患者累及多个关节,包括大关节和小关节;28.9%的患者仅累及单个关节。一些(33.3%)患者经影像学确诊,最常见的诊断是滑囊炎和滑膜炎。几乎所有病例都监测了两个非特异性炎症标志物,红细胞沉降率(ESR)和C反应蛋白(CRP),所有患者这两个标志物均有不同程度升高。大多数患者接受了糖皮质激素药物或非甾体抗炎药(NSAIDs)治疗。大多数患者的临床症状明显改善,26.7%的患者完全康复,随访几个月后无复发。为确定COVID-19疫苗接种与关节炎触发之间是否存在因果关系,未来需要大规模且严格对照的研究来验证这种关系,并进一步详细研究其发病机制。临床医生应提高对这种并发症的认识,以便早期诊断和适当治疗。